MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTX Stock Price Chart Interactive Chart >
MGTX Price/Volume Stats
| Current price | $13.59 | 52-week high | $18.45 |
| Prev. close | $13.37 | 52-week low | $11.60 |
| Day low | $13.33 | Volume | 45,200 |
| Day high | $13.81 | Avg. volume | 100,526 |
| 50-day MA | $13.40 | Dividend yield | N/A |
| 200-day MA | $14.60 | Market Cap | 602.24M |
MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.
Latest MGTX News From Around the Web
Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio DealThe promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others |
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis PigmentosaLONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR |
Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging HigherShareholders in MeiraGTx Holdings plc ( NASDAQ:MGTX ) may be thrilled to learn that the analysts have just delivered a... |
MeiraGTx Reports Second Quarter 2021 Financial and Operational ResultsLONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress. |
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue EstimatesMeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
MGTX Price Returns
| 1-mo | 1.49% |
| 3-mo | -12.32% |
| 6-mo | -3.69% |
| 1-year | 5.92% |
| 3-year | -0.07% |
| 5-year | N/A |
| YTD | -10.24% |
| 2020 | -24.38% |
| 2019 | 107.68% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...